

# Gemini Stock Analysis Report

---

Based on the detailed analysis of the provided **SUNPHARMA.NS** report (generated date 2026-01-10), here is my assessment.

## Step 1: Audit the Data

- **Data Present:**
  - **Price Structure:** Daily and Weekly candlesticks with EMAs (20, 50, 200).
  - **Trend Indicators:** Supertrend, MACD, Relative Strength (RS) Analysis.
  - **Volatility:** Bollinger Bands and Volatility Squeeze indicators.
  - **Fundamentals:** Revenue/EPS growth, ROE, and Broker Targets.
  - **Volume:** Volume moving averages and divergence analysis.
- **Data Missing:**
  - **Fibonacci Retracement Levels:** While not explicitly drawn, they can be inferred from the price swings.
  - **Sector Breadth:** While RS against CNXPHERMA is present, broader Pharma sector breadth (advance/decline) is not shown.
- **Confidence Level: High.** The report provides a comprehensive technical and fundamental picture, allowing for a high-probability assessment. *Note: The report date is Jan 2026; analysis is performed treating this as the "current" trading date.*

## Step 2: Analyze the Setup

- **Trend & Structure:**
  - **Long-Term: Bullish.** The stock is trading above the **200 EMA (1703.63)**. The weekly chart confirms a long-term uptrend.
  - **Intermediate/Short-Term: Bearish/Corrective.** The price (**1729.90**) is currently below both the **20 EMA (1749)** and **50 EMA (1743)**. The Supertrend (Daily) is in a **Downtrend (Sell)** status.
- **Momentum:**
  - **MACD: Bearish.** The MACD line is below the signal line, indicating negative momentum.
  - **RSI:** Neutral at **44.37**. It is failing to hold the bullish 50-60 zone, suggesting weak buying pressure.
- **Volatility:**
  - A **Volatility Squeeze** is detected (BB Width 0.0598). This indicates a violent move is imminent. Given that price is in the "Lower Half" of the Bollinger Bands and momentum is negative, the probability favors a downside breakout to test support before a rally.
- **Relative Strength:**
  - The stock has an RS Score of **49/100** and is rated "Neutral." It is not currently leading the market or its sector.

**Confluence Check:** There is a conflict between the long-term uptrend (200 EMA support) and immediate short-term weakness (Supertrend Sell + Price < 50 EMA). Entering now is effectively "catching a falling knife" before confirmed support.

## Step 3: Formulate the Recommendation

**Decision: NO** I advise **against** entering this stock at the current market price (CMP 1729.90).

**Reasoning:** While the long-term story is intact, the short-term technicals are deteriorating. The stock is stuck in a correction phase below key resistance (EMAs 20 & 50). The "Volatility Squeeze" combined with negative

# Gemini Stock Analysis Report

---

MACD increases the risk of a flush down to the 200 EMA (approx. 1700-1705) before a valid reversal occurs. Capital preservation dictates waiting for the trend to realign.

**Conditional Plan (Watchlist Setup):** We need the stock to prove it has finished correcting by reclaiming short-term momentum.

- **Condition to Buy:** Wait for a **Daily Close above 1,755**. This effectively clears the 20 EMA, 50 EMA, and the recent "Golden Cross Price" resistance, signaling a return of bullish control.
- **Entry Price: 1,755 - 1,760** (Buy Stop limit).
- **Stop Loss: 1,690** (Risk roughly 3.7%). This places the stop below the critical 200 EMA and the psychological 1700 level.
- **Take Profit:**
  - **Target 1: 1,850** (Recent swing highs, ~5.4% upside).
  - **Target 2: 1,955** (Analyst Target/Forecaster High, ~11% upside).

## News & Analyst Targets

Based on the latest search results for the week ending **January 10, 2026**, here is the research update for **Sun Pharmaceutical Industries Ltd. (SUNPHARMA)**.

### 1) Latest News for SUNPHARMA This Week (Jan 4 - Jan 10, 2026)

- **SPARC Restructuring & Layoffs:** On January 9, **Sun Pharma Advanced Research Company (SPARC)**, the research arm demerged from Sun Pharma, announced a significant restructuring. The company plans to cut its workforce by **40%**, with the impact largely concentrated in its US operations. This move is aimed at optimizing costs and reshaping its research model to a hybrid structure. While SPARC is a separate listed entity, its pipeline development is closely watched by Sun Pharma investors.
- **Trademark Litigation Loss:** On January 5, the **Bombay High Court** set aside an interim injunction Sun Pharma had previously secured against **Meghmani Lifesciences**. The dispute involved Sun Pharma's trademark "RACIRAF" versus Meghmani's "EsiRaft" for a heartburn medicine. The court ruled the marks were not deceptively similar, allowing Meghmani to continue marketing its product.
- **Regulatory Context (Baska Facility):** While the initial news broke in late December 2025, the **Official Action Indicated (OAI)** classification by the USFDA for Sun Pharma's **Baska manufacturing facility** continues to weigh on sentiment this week. The company has assured that supplies to the US will continue uninterrupted, but remediation efforts are in focus.

### 2) Upgrade or Downgrade from Brokerages

- **Jefferies (Upgrade/Target Raise):** On January 8, 2026, **Jefferies** maintained its **BUY** rating on Sun Pharma and **raised its target price to INR 2,100** (up from INR 2,000). The brokerage cited steady domestic growth and a strong outlook for the pharmaceutical sector in 2026.
- **Morgan Stanley (Commentary):** In a note dated January 8, Morgan Stanley flagged mixed regulatory risks for the sector. Specifically for Sun Pharma, they highlighted compliance risks at its generic injectable facility but noted that the company's strong **specialty product portfolio** limits the overall earnings risk.

### 3) Other News Impacting SUNPHARMA

- **Sector Sentiment:** The broader pharma sector is seeing renewed interest in 2026, with analysts predicting it to be a year of growth and re-rating. However, regulatory scrutiny remains high.
- **Competitor Activity:** **Granules India** received tentative USFDA approval for a generic ADHD medication this week. While not a direct hit to Sun Pharma's core specialty moat, it highlights the competitive intensity in the US generic market which Sun Pharma also navigates.

# Gemini Stock Analysis Report

## 4) Latest Analyst Targets (January 2026)

The following table summarizes the latest available price targets from major brokerages and consensus estimates for Sun Pharma.

Brokerage / Source	Rating	Price Target (INR)	Date / Status
Jefferies	BUY	INR 2,100	Jan 08, 2026 (Raised)
Consensus (Avg)	BUY	INR 1,952 - INR 1,955	Jan 10, 2026
Market High Est.	--	INR 2,450	12-Month High Forecast
Market Low Est.	--	INR 1,570	12-Month Low Forecast
Bank of America	Underperform	INR 1,570	Maintained (Prev. update Aug '25)

*Note: Targets are subject to change based on daily market performance. The current market price is trading in the range of INR 1,728 - INR 1,760.*


# Stock Detailed Analysis Report

**SUNPHARMA.NS**

Current Price: ₹1729.90

Generated: 2026-01-10 10:18

# SUNPHARMA.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	8.97%	10.64%
Net Income	Yes	No	14.12%	49.47%
ROE	Yes	No	0.61%	30.45%
EPS	Yes	No	14.29%	49.67%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	7.57%	2.54%
Net Income	No	5.99%	-4.31%
ROE	No	-32.32%	-32.32%
EPS	Yes	-4.72%	1.45%

# SUNPHARMA.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Neutral</b>
RS Score:	49.0/100

:

## == RS RATIOS ==:

1M RS:	<b>0.947 [Neutral]</b>
3M RS:	<b>0.989 [Neutral]</b>
6M RS:	<b>1.008 [Leader]</b>
1Y RS:	<b>0.983 [Neutral]</b>

:

## == TURNAROUND ANALYSIS ==:

Turnaround Status:	<b>Not Detected</b>
--------------------	---------------------


:

## SIGNAL CRITERIA::


✗ Emerging RS:	<b>Not accelerating</b>
✓ Medium-term Lagging:	1Y=0.983 ( $\leq 1.0$ )
✓ Performance Improving:	3M (+4.3%) > 6M (+3.6%)

Relative Strength Analysis: SUNPHARMA.NS vs ^CNXPHARMA  
Classification: Neutral


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline





## SUNPHARMA.NS - EMA Crossover Summary

EMA 20:	1749.20
EMA 50:	1743.32
EMA 200:	1703.63
Trend Status:	<b>Strong Uptrend</b>
Golden Cross Date:	2025-11-14 00:00:00+05:30
Golden Cross Price:	1757.10


SUNPHARMA.NS EMA Crossover Analysis



## SUNPHARMA.NS - Bollinger Bands Summary

Current Price:	1729.90
Upper Band:	1799.77
Middle Band (SMA 20):	1747.49
Lower Band:	1695.21
%B:	0.3318
Band Width:	0.0598
Status:	Lower Half
Signal:	None
Recent Signal 1:	<b>Sell Signal at 2025-12-01 00:00:00+05:30</b>


SUNPHARMA.NS Bollinger Bands (20, 2) Analysis



## SUNPHARMA.NS - Supertrend Summary

Status:	<b>DOWNTREND (Sell)</b>
Supertrend Value:	1788.19
Signal Identified On:	2025-12-18


Supertrend Analysis for SUNPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## SUNPHARMA.NS - MACD Summary

MACD Line:	-4.99
Signal Line:	-6.36
Histogram:	1.38
Trend:	<b>Bullish</b>
Momentum:	<b>Weakening</b>
Signal:	None

SUNPHARMA.NS Price



SUNPHARMA.NS MACD (12, 26, 9)








## SUNPHARMA.NS - Volatility Squeeze Summary

<b>BB Width:</b>	0.0598
<b>ATR:</b>	24.6928
<b>Total Signals:</b>	27
<b>Signal 1:</b>	ATR Contraction at 2026-01-01 00:00:00+05:30 (Price: 1721.10)
<b>Signal 2:</b>	ATR Contraction at 2026-01-02 00:00:00+05:30 (Price: 1728.00)
<b>Signal 3:</b>	ATR Contraction at 2026-01-05 00:00:00+05:30 (Price: 1728.90)
<b>Signal 4:</b>	ATR Contraction at 2026-01-06 00:00:00+05:30 (Price: 1760.20)
<b>Signal 5:</b>	ATR Contraction at 2026-01-07 00:00:00+05:30 (Price: 1782.60)




# SUNPHARMA.NS - Volatility Squeeze Analysis



# SUNPHARMA.NS - RSI-Volume Summary

Current RSI:	44.37
Current Volume:	1585689
Volume MA 20:	1787393
Bullish Divergences:	1
Bearish Divergences:	3
Bullish Div 1:	Date: 2025-06-04 00:00:00+05:30, Price: 1659.44
Bearish Div 1:	Date: 2024-04-01 00:00:00+05:30, Price: 1609.07
Bearish Div 2:	Date: 2025-07-30 00:00:00+05:30, Price: 1733.80

# SUNPHARMA.NS RSI-Volume Divergence Analysis



## Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	1705.86	1729.9	2025-11-10
1 Day	DOWNTREND (Sell)	1788.19	1729.9	2025-12-18
15 Min	DOWNTREND (Sell)	1742.74	1736.1	2026-01-07

## Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bullish	Weakening	No Signal
1 Day	Bullish	Weakening	No Signal
15 Min	Bullish	Strengthening	Bullish Crossover (Buy)

SUNPHARMA.NS - 1 Week (Candlestick + EMAs)




SUNPHARMA.NS - 1 Day (Candlestick + EMAs)



SUNPHARMA.NS - 15 Min (Candlestick + EMAs)



## Trendlyne Snapshot - SUNPHARMA\_main



OverviewFORECASTERSTOCK REPORTBuy Sell ZoneF&OFinancialsNewsReportsTechnicalsShareholdingDealsCorporate ActionsAlertsAbout

Durability score <sup>1</sup>

65.0 / 100

High Financial Strength

Valuation Score <sup>1</sup>

31.0 / 100

Mid Valuation

Momentum Score <sup>1</sup>

55.2 / 100

Technically Neutral

Mid-range Performer These stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to i... [View Similar](#) [Embed DVM](#) [</>](#)

18

S W

7

1 O T 1

SWOT Analysis [</>](#)

#### Check Before You Buy

VIEW FULL CHECKLIST

High rank 14 Positive \* 9 Negative

60.9% Pass in checklist

0 45 55 100

#### PE Valuation Check

Right Now <sup>1</sup> Undervalued 25.2%

1 Year Forward <sup>1</sup> Undervalued 39.7%

INSIGHT Sun Pharmaceutical is undervalued at both current PE and future earnings esti

### Sun Pharmaceutical Key Metrics

Preset Metrics

Preset Metrics

ROE Ann. % <a href="#">&gt;</a> Above Industry Median	15.1	Broker Average Target <a href="#">&gt;</a> 11.07% upside	1,921.38	Market Capitalization <a href="#">&gt;</a> Market Leader	415,061	Price to Book <a href="#">&gt;</a> Above Industry Median
--	------	---	----------	---	---------	---

ABOUT

Incorporated in 1993, Sun Pharmaceutical Industries (Sun Pharma) is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulation and Active Pharmaceutical Ingredients (APIs). It offers innovative ... [Read More](#)

DVM

Key Metrics

Price Chart

Forecaster

Financials

Technicals

Shareholding


Deals

Documents

Corporate actions

Company Profile [X](#)

Trendlyne Snapshot - SUNPHARMA\_forecaster



Sun Pharmaceutical - SUNPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 38 analysts

Sun Pharmaceutical has a share price target of Rs 1955, revenue growth forecast of 9.1%, and profit growth estimate of 2.7% for FY26, based on top 38 analyst calls.

Sun Pharmaceutical **FORECASTER** - Analyst Estimates <sup>1</sup>

[FORECASTER DASHBOARD](#) →

